This grant, valued at approximately $600,000 over two years, will be used to develop enhancements to the company’s vectors for vaccine applications against malaria.
Rick King, GenVec’s senior vice president of research, said: “In addition to advancing our malaria vaccine program, work under this grant may provide improvements to our technology that could be applied to other adenovector-based vaccines and therapeutics.”